Computer System Validation in Life Sciences: Key Steps, Documentation, and Compliance Considerations

Several regulations and guidance documents shape life sciences compliance for computerized systems:

Two recent changes to watch:

FDA's CSA guidance is final. FDA finalized Computer Software Assurance for Production and Quality System Software in September 2025. It replaces Section 6 of the 2002 General Principles of Software Validation, and it encourages effort in proportion to risk, including unscripted testing where risk is low (Hogan Lovells).

Annex 11 is being revised. The European Commission consulted on a revised Annex 11, a revised Chapter 4 on documentation and a new Annex 22 on artificial intelligence from 7 July to 7 October 2025 (European Commission). Check whether the final versions have been published before relying on the draft text.

The common thread is a shift from documentation-heavy validation to risk-based, critical-thinking approaches. The focus is on what really affects patient safety, product quality and data integrity. 

The validation lifecycle runs from first concept to retirement. A typical risk-based approach, in line with GAMP 5, follows these steps:

1. Assess GxP impact. Decide whether the system affects patient safety, product quality or data integrity. If it does not, full validation may not be needed.
2. Plan the validation. Write a validation plan that sets the scope, approach, roles, deliverables and acceptance criteria.
3. Define requirements. Capture user requirements, including regulatory needs such as audit trails, e-signatures and data retention.
4. Assess risk. Identify which functions are high risk, and focus testing effort on them.
5. Assess the supplier. Evaluate the vendor's quality system and documentation, and reuse their testing where it is justified.
6. Specify and configure. Document the functional and configuration specifications, then build or configure the system.
7. Verify and test. Carry out Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ), or equivalent risk-based testing. Use scripted tests for high-risk functions and unscripted testing where risk is low.
8. Trace and report. Link every requirement to its tests, resolve deviations, and issue a validation summary report to release the system.
9. Operate in a validated state. Maintain change control, periodic reviews, incident management, backup and recovery, and access reviews.
10. Retire the system. Migrate or archive the data, keep records readable for their retention period, and decommission the system under control.

Inspectors look for a clear, traceable record of how the system was validated. Scale each deliverable to the system's risk.

• Data integrity. Design systems to meet the ALCOA+ principles: data must be attributable, legible, contemporaneous, original and accurate, as well as complete, consistent, enduring and available. Configure audit trails, unique user IDs and secure time stamps, and review audit trails regularly.
• Electronic records and signatures. Make sure e-signatures are linked to their records, include the signer's name, date and meaning, and cannot be repudiated.
• Risk-based effort. Spend validation effort where risk is highest. Over-documenting low-risk functions wastes time without improving compliance.
• Cloud and SaaS systems. Use supplier audits, quality agreements and the vendor's own testing. Define who controls updates, and assess each vendor release before it reaches production.
• Change control. Assess every change, patch and upgrade for GxP impact, and re-test proportionately.
• Access and security. Apply role-based access, review user access periodically, and protect against cyber threats.
• Business continuity. Validate backup, restore and disaster recovery, and test them regularly.
• AI and machine learning. Expect new requirements for AI used in GMP, such as those in the EU's draft Annex 22. Requirements will cover training data, model performance, explainability and human oversight.

• Validating too late. Bolting validation onto a finished project instead of building it in from the start.
• Testing everything equally. Applying heavy scripted testing to low-risk functions while missing high-risk ones.
• Weak requirements. Vague user requirements that cannot be tested or traced.
• Ignoring the vendor. Neither assessing suppliers nor reusing their documentation.
• Letting the validated state lapse. Making changes after go-live without proper change control or periodic review.
• Treating audit trails as a formality. Configuring them but never reviewing them. 

Specialist CSV validation services can help when:

• You are implementing or upgrading major GxP systems, such as ERP, LIMS, MES, QMS or eTMF, and lack in-house validation capacity.
• You are moving from traditional CSV to a risk-based CSA approach.
• You are adopting cloud, SaaS or AI tools and need a validation strategy that fits.
• You are preparing for an FDA or EMA inspection, or responding to observations.
• You need remediation of legacy systems or data integrity gaps.

A good partner brings GAMP 5 expertise, templates and accelerators, and independent quality oversight. They should also transfer knowledge to your team. 

Effective computer system validation in life sciences is no longer about producing the most paperwork. It is about showing, with risk-based evidence, that systems protect patients, product quality and data. Follow a clear lifecycle, keep documentation proportionate and traceable, and keep systems in a validated state long after go-live.

With regulations changing, including FDA's final CSA guidance and the EU's revisions to Annex 11, now is a good time to review your approach to life sciences compliance. Bring in experienced CSV validation services where you need extra capacity or expertise.